Google DeepMind spinout Isomorphic Labs raises $5 billion to develop AI-powered drugs
Isomorphic Labs, the AI drug discovery company founded by Google DeepMind CEO and Nobel laureate Demis Hassabis, has raised $5 billion in fresh funding to accelerate the development of AI-designed medicines. The massive investment comes as the London-based company nears a critical milestone: testing whether AI-designed drugs can deliver results in human clinical trials.
Greenoaks and Sequoia Capital co-led the oversubscribed Series C round, with participation from Andreessen Horowitz (a16z), Alphabet, and several other investors. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund participated in the financing.
Announced Tuesday, November 17, the funding represents one of the largest investments in AI-driven drug discovery, reflecting growing investor confidence that artificial intelligence could fundamentally change how pharmaceutical companies develop new treatments.
“Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines,” Sir Demis Hassabis, founder and CEO of Isomorphic Labs, said in a post on X.
For Isomorphic Labs, the stakes are enormous. Developing a new medicine can take more than a decade, with many promising compounds failing before reaching patients. The company believes AI can help researchers identify better drug candidates earlier, reducing expensive trial-and-error work that has long slowed pharmaceutical research.
From Google DeepMind’s AlphaFold Breakthrough to AI-Designed Medicines
Founded in 2021, Isomorphic Labs emerged from research pioneered at Google DeepMind, the AI laboratory behind AlphaFold, which made major advances in predicting protein structures.
Hassabis, who shared the 2024 Nobel Prize in Chemistry for work related to protein structure prediction, is now pursuing an ambitious next step: using AI to design medicines rather than merely predict how biological molecules are structured.
At the center of that effort is IsoDDE, Isomorphic Labs’ proprietary AI drug design engine. The system combines foundation models that can simulate molecular interactions across different diseases and drug types.
“Isomorphic Labs is focussed on designing and developing new medicines with AI, ushering in a new era of biomedical breakthroughs. The company is scaling its proprietary drug design engine (IsoDDE) and therapeutic candidate pipeline designed with AI to deliver the next generation of medicines for patients,” the company said, announcing the funding.
Its goal is to help scientists explore enormous numbers of possible molecular structures, predict their behavior, and identify candidates with properties suitable for further drug development.
Isomorphic Labs says its technology is already producing positive preclinical results across its internal oncology and immunology programs and collaborations with pharmaceutical partners.
Those findings are encouraging, but they remain preclinical. The company has yet to establish that its AI-designed treatments are safe and effective in humans, a distinction that will become increasingly significant as its programs approach clinical trials.
The fresh capital will support further development of IsoDDE, additional research into disease biology, and the infrastructure required to move promising drug candidates from computer models into clinical testing.
“When we founded Isomorphic, our conviction was that biology could be understood and modeled at the most fundamental molecular level and radically accelerated through AI,” said Sir Demis Hassabis, founder and CEO of Isomorphic Labs.
“Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
A $5 Billion Bet on the Future of Drug Discovery
The investment highlights a growing shift in how AI companies are attracting capital. Much of the industry’s attention has centered on chatbots, coding assistants, and generative AI applications. Isomorphic Labs is pursuing a different opportunity: applying AI to one of the most expensive and failure-prone areas of scientific research.
The potential payoff is substantial. A platform that consistently identifies promising drug candidates faster could reshape pharmaceutical research, shorten early discovery timelines, and improve the economics of bringing new treatments to market.
Isomorphic Labs is developing its own drug pipeline alongside partnered research programs. This approach gives the company multiple paths to commercial success, from advancing proprietary medicines to working with established pharmaceutical companies.
Max Jaderberg, president of Isomorphic Labs, said the company’s models are producing repeatable scientific advances that translate into improved molecular candidates.
The financing will support continued investment in AI research, laboratory capabilities, clinical development operations, and global bioengineering infrastructure. Isomorphic Labs is headquartered in London and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
Still, billions in funding cannot eliminate the biological uncertainty that makes drug development difficult. Molecules that perform well in computer simulations and laboratory experiments can fail in human trials for reasons that even sophisticated AI systems cannot reliably predict.
That makes the company’s next stage especially important.
For investors backing Isomorphic Labs, the $5 billion commitment is a bet that AI can move beyond predicting biology to producing medicines that work.
The real breakthrough will come when an AI-designed drug proves it can help patients, not merely impress researchers in a laboratory.

Sir Demis Hassabis, PhD Founder and CEO
